In Reply The AREDS2 trial provided a unique opportunity to evaluate the effects of oral supplementation on cognition. The limitations of our study included testing in a well-nourished, well-educated, select population affected with age-related macular degeneration. We noted the restricted generalizability of the results to this population and the possibility that the doses and ratios of various omega-3 LCPUFAs were inappropriate.
Concerning the remarks of Dr Renzi-Hammond and colleagues, our study was designed to evaluate the main effects of the individual nutrients, specifically omega-3 LCPUFAs. We agree that this was not a placebo-controlled study. We described the fact that the majority of participants were using some form of AREDS supplements that contained antioxidant vitamins C, E, and beta-carotene, which were tested in previous trials of cognition with no definitive beneficial effects.1
Chew EY, Launer L, Bernstein P. Oral Nutrient Supplementation and Cognitive Function—Reply. JAMA. 2016;315(5):516–517. doi:10.1001/jama.2015.16467